Takeda Pharmaceutical Company Limited

Solent Therapeutics, LLC

Simone Bigi

Steve Swann

Masaki Seto

Anthony R Gangloff

Steven John Woodhead

Phong H Vu

Mitsunori Kono

Zenyu Shiokawa

Tony Gibson

Walter Keung

Alison L Chambers

Angie Vassar

Jason Pickens

Feng Zhou

Allison L Chambers

Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R, R, R, Rand Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2

Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.

Heteroarylamide inhibitors of TBK1

Growing community of inventors

San Diego, CA, United States of America

Simone Bigi